Atopic Dermatitis
Pipeline by Development Stage
Drug Modality Breakdown
Atopic Dermatitis is a $6.0B market in growth phase, driven by rapid innovation in biologic and small-molecule immunotherapies.
Key Trends
- JAK inhibitors dominating 50% of market share with multiple launches reaching peak sales
- Shift from topical corticosteroids to systemic biologics (IL-13, IL-5 antagonists, TSLP blockers)
- Patent cliff concentration 2026-2028 creates M&A and generic opportunity windows
Career Verdict
Strong career opportunity for specialists willing to build expertise in immunology-focused dermatology, with 6,216 active roles and sustained hiring across commercial, R&D, and clinical operations.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ADBRY (tralokinumab-ldrm) | Leo Pharma | $32M | 0.5% | Peak | Growing | |
| 2 | EUCRISA (crisaborole) | R-Pharm US | $10M | 0.2% | Peak | Stable | 4.2yr |
| 3 | CIBINQO (abrocitinib) | Pfizer | $10M | 0.2% | Peak | Growing | 9.7yr |
| 4 | ELIDEL (pimecrolimus) | Bausch + Lomb | $870K | 0.01% | Loss of Exclusivity Approaching | Declining |
Drug Class Breakdown
rapid expansion and market consolidation
stable to declining as older class
emerging novel targets
niche but growing segment
emerging first-in-class opportunity
new entrant, moderate uptake
stable niche category
Career Outlook
GrowingAtopic dermatitis is a high-growth specialty supported by 598 active clinical trials, market expansion from $6.0B, and sustained corporate hiring across all major pharma companies. The disease area benefits from multiple mechanism classes in late-stage development and strong differentiation between branded assets, reducing commoditization risk for specialists. However, patent cliffs in 2026-2030 will create cyclical hiring volatility, particularly affecting small-molecule and topical specialists.
Breaking In
Enter via Commercial (Brand Manager, Sales) or Clinical Operations (Associate roles) at top-4 companies (Abbott, AbbVie, AstraZeneca, GSK); atopic dermatitis offers shorter learning curves than oncology with strong peer mentoring infrastructure.
For Experienced Professionals
Experienced professionals should pursue Clinical Operations ($307K avg), Medical Affairs, or real-world evidence roles where JAK inhibitor safety and outcomes expertise commands premium compensation amid patent cliff uncertainty.
In-Demand Skills
Best For
Hiring Landscape
Atopic dermatitis represents a high-hiring-volume specialty within immunology, with 6,216 total active roles concentrated in Commercial (1,328 jobs, 21%), Manufacturing (644 jobs, 10%), and R&D (430 jobs, 7%). Abbott, AbbVie, and AstraZeneca lead hiring demand with 1,499, 1,051, and 1,029 jobs respectively. Commercial roles command the highest average salary ($257K), while Clinical Operations roles offer the premium compensation at $307K average.
Top Hiring Companies
By Department
Highest demand is in Commercial and Clinical Operations roles; Clinical Operations offers the largest salary premium ($307K avg), making it an attractive specialty for quantitatively-oriented professionals.
On Market (8)
Approved therapies currently available
Competitive Landscape
124 companies ranked by most advanced pipeline stage
+94 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 8,192 patients across 50 trials
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Tralokinumab for Dupilumab Failures
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
Ethnic Differences in Mechanisms of Action of Dupilumab
Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
Dupixent and Narrowband UVB for Atopic Dermatitis
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Steroid-reducing Effects of Crisaborole
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover
Investigation of Flare and Remission in Subjects With Atopic Dermatitis
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
Management of Pruritus With Xyzal in Atopic Dermatitis
VANOS Cream and Skin Barrier Function
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
Combination Therapy for Atopic Dermatitis
A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
A Study of MG-K10 in Chronic Spontaneous Urticaria
A Study of Lebrikizumab in Adults With Nummular Eczema
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
Study of CM310 in Adolescent Subjects With Atopic Dermatis
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Related Jobs in Immunology
Senior Principal Scientist, Clinical Operations - Immunology
District Manager
Key Account Manager Dermatology, Scotland - one year contract
Dermatology Health and Science Specialist - Grand Rapids, MI
Senior Research Associate, Biologics
Chef(fe) de Produits Sevrage Tabagique et dermatologie OTC France - Alternance - H/F
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.